Aspargo’s Global Launch Plan
EUROPE
SPAIN
Penetrate the Bandol®
market with a PCP
salesforce
MEXICO
2024
EUROPE
GERMANY,
NETHERLANDS,
IRELAND
2024
UK
2024
GULF REGION
SAUDI ARABIA, KUAWAIT,
UAE, QUATAR, BAHRAIN,
OMAN, LEBANON,
EGYPT, IRAQ
2024
US / CANADA
2025
2022
2023
2024
2025
SOUTH AMERICA
ARGENTINA
2024
REST OF EUROPE
2024
REST OF CENTRAL & SOUTH AMERICA
2024
JAPAN
2024
Aspargo Is Pursuing a Multipronged Approach
for International Expansion.
Organic Growth
Grow Aspargo’s global franchise
by retaining full ownership rights
and marshalling internal and contract
resources to enhance sales and profits.
License
Enter into license agreements with local
country pharmaceutical companies to
generate revenue through milestone
and royalty payments.
Joint Venture
Collaborate with local country
partners to access foreign markets
efficiently and quickly; share revenues
and expenses.
Manufacturing & Packaging
Aspargo is partnering with Syneos Health to develop a global commercialization plan with multi-channel programs designed to ensure Sildenafil Oral Spray launch success.
Sildenafil spray is manufactured and packaged on behalf of Farmalider by Edefarm Laboratorios, a contract manufacturer of pharmaceuticals located in Valencia, Spain.
Edefarm has transferred all manufacturing technology, analytical methods and know-how to Pii.
Pii has confirmed and augmented the analytical methods developed by Farmalider and Edefarm, is conducting the required stability studies on the drug product and is manufacturing the clinical supplies and commercial batches needed for our clinical study and FDA submissions.
Strategic & Potential Partnerships
Market Exclusivity & IP Protection
Aspargo has licensed the exclusive rights to commercialize Sildenafil Oral Spray in the United States and more than 30 countries throughout Europe, the United Kingdom, the Middle East, Asia, Canada and South America from Farmalíder, S.A. (Madrid, Spain), a leader in the Spanish OTC and ibuprofen market.
Sildenafil Oral Spray market exclusivity is protected by trade secrets and manufacturing know-how necessary to manufacture the drug product without compromising drug stability or efficacy.
Aspargo is protecting its custom designed spray bottle with US and international patent applications.
US
Patent No. 10,016,428
Granted: July 10, 2018
Expiration: March 2036
Europe
Patent No. EP3072515
Granted: February 28, 2018
Expiration: March 2036
Mexico
Patent No. 369760
Granted: November 20, 2019
Expiration: March 2036